Physician Payment Sunshine Rule is Finalized

by Baker Donelson

The Final Rule implementing the Physician Payment Sunshine Act was announced on February 1st and published in the Federal Register on February 8th. The Final Rule establishes procedures for drug and device manufacturers to submit annual reports to CMS of virtually all payments and other transfers of value to physicians and teaching hospitals – so-called Transparency Reports. The Final Rule also sets procedures for drug and device manufacturers and group purchasing organizations to report ownership interests (if any) held by physicians – so-called Ownership Reports.

The much-anticipated Final Rule contains few surprises for those familiar with the proposed rule, but it does incorporate several adjustments intended to ease the reporting burden. Chief among these changes is the implementation schedule. Entities required to collect and report data under the Sunshine Act will not need to begin collecting data until August 1, 2013 and will not need to make their initial reports until March 31, 2014.

As with so many rules in the health and life sciences space, the devil is in the details (or lack of details). The Final Rule imposes new burdens on drug and device manufacturers as well as GPOs with physician ownership. The regulations provide helpful guidance, but as companies struggle to meet these new burdens, there will be many unanswered questions. The Final Rule also has significant implications for physicians and teaching hospitals whose dealings with drug and device manufacturers and GPOs will be subject to greater public scrutiny.

Reports of Transfers of Value (Transparency Reports)

The Final Rule, mirroring the statute, is primarily divided between descriptions of the reports of payments and other “transfers of value” and reports of physician ownership and investment interests. CMS has elected to require that each type of report be made separately, even though the two types of reports share multiple data points and other similarities. In fact, several defined terms identified in the Transparency Reports section apply to Ownership Reports as well.

Applicable Manufacturer

Manufacturers subject to the reporting requirements are termed Applicable Manufacturers. The term is defined broadly to include any entity “operating in the United States” that is “engaged in the production, preparation, propagation, compounding, or conversion of a covered drug, device, biological, or medical supply” or is “under common ownership” with an entity that so manufactures and “provides assistance or support” to the entity with regard to the identified manufacturing tasks. Common ownership is defined to include ownership interests of 5 percent or greater. The definition specifically excludes entities which are not operating in the United States, distributors or wholesalers who do not take title to any covered item, and entities which manufacture drugs, devices, biological or medical supplies solely for use by or within the entity itself or by the entity’s own patients (such as a compounding pharmacy, so long as certain rules specific to pharmacies are met).

Entities will be considered to operate in the United States where they either have a physical location within the United States or are “otherwise conducting activities within the United States or in a territory, possession, or commonwealth of the United States.” Notably, the Final Rule specifically provides that entities operating in the United States may not avoid reporting obligations by passing payments through offshore affiliates or subsidiaries. Such payments would be considered “indirect” but must still be reported.

In general, an Applicable Manufacturer must report ALL transfers of value, including those unrelated to covered products. The Final Rule provides that, in the following limited scenarios, manufacturers need only report transfers related to the specific covered product manufactured:

  • Manufacture on behalf of another entity and are not involved in any marketing or distribution of the manufactured product; or
  • Receive less than 10 percent gross revenue yearly from the manufacture of covered products; or
  • Function as a separate operating division of an Applicable Manufacturer that does not produce any covered products and do not provide “assistance and support” to divisions that do.

Covered Drug, Device, Biological, or Medical Supply (Covered Product)

In response to public comments, the definition of a Covered Product was altered to clarify that a Covered Product “is one for which payment is available under Medicare, Medicaid, or CHIP” and which requires a prescription or premarket approval by, or notification to, the FDA. Payment is “available” whether it is made individually for the specific product or as part of a bundled reimbursement payment (such as the hospital inpatient prospective payment system).

Two broad categories of drugs and medical devices were excluded from the definition of Covered Products: (1) over-the-counter (OTC) prescription drugs and (2) medical devices that do not require premarket approval or notification to the FDA. Accordingly, medical device manufacturers that manufacture only Class I and certain Class II medical devices or only OTC prescription drugs will be exempt from the reporting requirements.

Covered Recipients

CMS rejected most comments that sought to narrow the definition of covered recipients, generally maintaining the broad statutory definition (any physician, as defined by 42 U.S.C. 1395x, and any teaching hospital). The definition specifically excludes bona fide employees of the Applicable Manufacturer as well as residents (who may or may not be licensed as physicians, depending on their state of practice). Teaching Hospitals are defined as facilities which received IME, GME, or psychiatric hospital IME during the most recent year data is available. Teaching Hospitals will be identified by CMS in a published list.

Payments or other Transfers of Value

The Final Rule does not alter the definition of a payment or other transfer of value (which is defined to include “a transfer of anything of value”) but does provide that a transfer must have discernible economic value, that all taxes, shipping, and other fees should be included in any calculation of value, and that manufacturers are free to include, in their voluntary “assumptions document,” an explanation of how values were calculated.

Transparency Report Contents

The specific categories of information required to be reported are set forth in section 1128G of the Social Security Act. The Final Rule, however, provides some insight regarding certain items on the list:

  • For payments made over multiple dates, CMS is providing manufacturers the flexibility to report either multiple dates or a single line item for the first date.
  • If a payment is not related to any covered product, manufacturers should report “none.” If it is related to a non-covered product, they should report “non-covered product.” If it is related to both a covered and non-covered product, they should report the covered product by name and may report the non-covered product in the fields for associated products. If it is related to more than one covered product, manufacturers may report up to five covered products by name.
  • The form of payment and nature of payment requirements have been finalized as proposed. CMS notes that “form of payment” should be the “modality used to transfer value” and “nature of payment” should be the reason the payment was made.
  • One form of payment has been divided: “stock, stock options, and other ownership investment interests” are now separated from “dividends, profits, and other returns of investment.”
  • “Space rental and facilities fees” has been added as a new nature of payment category.
  • For meals in group settings, manufacturers should report the per-person cost for each Covered Recipient who actually takes part in the meal.
  • An additional nature of payment category has been added for “compensation for serving as faculty or as a speaker for an accredited or certified continuing education event.”
  • The category “other” has been eliminated from the nature of payment options.
  • The Transparency Report may, but is not required to, include an assumptions document providing the assumptions and methodologies used by Applicable Manufacturers to calculate their disclosures. CMS does not intend to use the assumption document for prosecution purposes, but notes that it would be available for such use.
  • Research payments, in order to be considered research, need only a written agreement or contract or a research protocol. The Final Rule, unlike the proposed, does not require both. An unbroken chain of agreements between a manufacturer, a contract research organization (CRO), a site management organization (SMO) and a teaching hospital would be considered a written agreement for this purpose.
  • Reporting Research Payments has been streamlined so that each payment is reported once and includes the names of both the entity paid as well as the name(s) of the principal investigator(s).


CMS noted in the Final Rule that it lacked authority to expand the relationships excepted from reporting beyond those provided in the statute. It added some clarifications, however, to the existing categories:

  • Existing personal relationships (a gift from one spouse to another, for instance) will not need to be reported.
  • Payments or transfers that are each less than $10 and collectively amount to less than $100 per year need not be reported. These amounts will remain $10/$100 for the data collected in 2013 but will increase indexed to inflation for 2014 and beyond. Where small payments exceed $100 annually, manufacturers have the option of bundling small payments (in the same nature of payment category) as long as they indicate the method used and report consistently.
  • Small items ($10 or less) provided at events that are open to the public (such as conferences) are exempt from reporting entirely, and need not be tracked. Items exceeding $10 in value do need to be tracked, even at large scale, open events.
  • “Educational materials that directly benefit patients or are intended for patient use” is to be interpreted broadly, but not without limits. The definition has been broadened to include wall hangings and anatomical models that are intended to be used with patients, but specifically excludes journals and textbooks that are meant for physician use (even though such use may eventually benefit patients).
  • Discounts and rebates need not be reported.
  • In-kind items provided for charity care are exempt from reporting. CMS clarified that manufacturers need not track how each item is used, noting that a written agreement that the items will be used only for charity care would be sufficient.
  • Product samples remain excluded from the reporting requirement. CMS clarified that devices or evaluation equipment may meet this exception where they are intended for patient use. CMS again noted that, in lieu of tracking how each item is used by the recipient, the parties may enter into a written agreement that the products will be provided to patients.
  • Loans of covered devices for a short-term trial remain exempted from reporting, but CMS has clarified that the loan period may not exceed 90 days. Those that do must be reported as having begun on the 91st day.
  • Items or services provided pursuant to a contractual warranty remain excluded. CMS has slightly expended this provision to also include items and services provided according to maintenance or service contracts.
  • Covered recipient acting as a patient: CMS maintained this exception for transfers made to a covered recipient that is acting as a patient, not as a physician. The Final Rule also clarifies that this exception also applies to a physician who is a subject in a research study (in a non-professional capacity).
  • CMS clarified that the exception permitting transfers related to health care services provided to a covered recipient as a result of a self-insured health plan applies also to the covered recipient’s family members who also participate in the plan.
  • Exceptions for transfers to a covered recipient who is also a non-medical professional (a physician who is also an attorney, for instance) relating solely to the non-medical services of the covered recipient and for transfers made to a covered recipient as payment for services with respect to civil, criminal, or administrative proceedings were both adopted without change.

Indirect Payments and Transfers

CMS acknowledged that manufacturers may have difficulty in determining and reporting indirect payments and transfers that are handled first by a third party and then transferred to the covered recipient. Several commentators were concerned about whether the manufacturer was either aware of the identity of the covered recipient or had control in the selection of the covered recipient. The Final Rule rejects both the awareness and control standards. Instead, the Final Rule adopts a False Claims Act knowledge standard that requires manufacturers to report payments or transfers of value when it “knows” of the covered recipient, i.e., the manufacturer has actual knowledge of a covered recipient, acts in deliberate ignorance of the covered recipient, or acts in a reckless disregard to the truth or falsity of the existence of the covered recipient. CMS explained that manufacturers and GPOs should be familiar with that False Claims Act knowledge standard and should be able to apply it easily.

The Final Rule also clarifies some bright-line examples of reportable and not-reportable indirect payments and transfers. First, manufacturers will be required to report indirect payments when the manufacturer directs that the payment or transfer be made to any covered recipient. Second, payments made to physicians participating in a double-blind market research study conducted by a third party engaged by a manufacturer will not be considered a reportable indirect payment or transfer of value because of the inherent nature of the double-blind study. Third, indirect payments made to covered recipients to conduct CME will not be considered a reportable payment if: (i) the program is appropriately accredited; (ii) the manufacturer does not select the speaker or provide a list of approved speakers for the program; and (iii) the manufacturer does not directly pay the covered recipient. CMS declined to accept threshold exclusions based on whether the manufacturer does not control the selection of the covered recipient by the third party, whether the payment is made to a medical society (or other professional society), or whether the payment is related to Risk Evaluation Mitigation Strategies required by the FDA.

In response to comments from manufacturers, CMS will not require manufacturers to indefinitely monitor their payments to third parties in an attempt to identify indirect payments or other transfers to covered recipients. The Final Rule requires manufacturers to report those indirect payments or transfers to a covered recipient during the reporting year and up to the end of the following second calendar quarter.

Delayed Publication of Research Payments and Clinical Investigations

The Final Rule essentially adopts the provisions of the proposed rule with regard to delayed publication of payments for research and/or clinical investigation. All payments that are related to research related to new products will be granted a delay. Generic products will be considered “new products,” including drugs receiving approval under an Abbreviated New Drug Application or devices seeking approval under the 501(k) process. Payments related to new applications of existing products will be granted a delay only where the research does not meet the definition of a clinical investigation. Clinical investigation has been defined broadly to mean Phases I through IV clinical research for drugs and biologicals and approval trials for devices. Finally, CMS clarified that a payment can only be granted delayed publication where it meets the definition of research – including the requirement that it include either a written agreement or a written research protocol (though CMS does not intend that manufacturers provide these materials to CMS for verification).

Ownership Reports

Physician Ownership Reports

The Sunshine Act requires Applicable Manufacturers and Applicable Group Purchasing Organizations (GPO) to report direct and indirect ownership and investment interests of physicians and the immediate family members of physicians. CMS acknowledged relying on existing Stark law definitions for many of the key terms and definitions for Ownership Reports. As mentioned above, many of the key definitions for Ownership Reports are included under the discussion of Transparency Reports. For example, an Applicable Manufacturer is defined the same for both rules, although an Applicable Manufacturer has to make separate Transparency and Ownership Reports.

Group Purchasing Organizations

GPOs are required to submit reports on physicians, and their immediate family members, who own an interest in the GPO. CMS defined an Applicable Group Purchasing Organization to include any entity that (1) operates in the United States, or a territory or commonwealth of the United States, and (2) “purchases, arranges for or negotiates the purchase of a covered drug, device, biological, or medical supply for a group of individuals or entities, and not solely for use by the entity itself.” CMS explained that the intent of the rule is to include those entities that purchase goods and devices for resale to others and for distribution to groups of individuals or other entities. CMS also explained that this definition includes physician-owned distributors (PODs) of those items. However, a GPO that does not have ownership held by a physician or an immediate family member of a physician does not have to report to CMS.

CMS declined to expand the definition of Applicable GPO to include other entities, which should result in fewer GPOs reporting to CMS. For example, CMS excluded group purchasing entities that purchase covered products only for use by commonly owned entities, such as those sometimes found in hospital health systems. CMS also limited Applicable GPOs to only those organizations that purchase for a group. In response to other comments, CMS agreed that an Applicable GPO would not include “rare and circumstantial resale” of products in response to drug shortages.

As a general rule, Applicable GPOs are not required to report payments to physicians. However, Applicable GPOs must report payments and transfers of value to those physicians who have ownership or investment interests. Applicable GPOs report this information as part of their Ownership Report requirement, using the same reporting requirements as Applicable Manufactures use for Transparency Reports.

Immediate Family Members and Ownership or Investment Interests

The Final Rule’s definition of immediate family members is identical to the list of immediate family members found in the Stark law regulations: a physician’s spouse, parents, children, siblings, stepparents, stepsiblings, in-laws, grandparents, spouses of grandparents and grandchildren. Both natural and adoptive family members are included as immediate family members.

Similarly, the Final Rule’s definition of ownership or investment interests is similar to the traditional Stark law definition. Stock, stock options (as equity), partnership shares, limited liability company memberships or units, loans, bonds and other financial instruments that are secured with an entity’s property or revenue are all included as an ownership or investment interest. Also like Stark, an interest held in an employer-based retirement plan, unsecured loans, stock options received as compensation, and publicly traded securities are excluded from the definition of ownership or investment interests and need not be reported.

Stock options pose a more vexing question for manufacturers and GPOs. Some stock options will be considered ownership or investment interests and should be reported in the Ownership Report. Other stock options could be considered payments or transfers of value and should be reported under the Transparency Report. Still other stock options might not need to be reported until exercised.

CMS acknowledged in the Final Rule that GPOs and manufacturers could have some difficulty identifying, or knowing, the immediate family members of physicians. The Final Rule does not require physicians to disclose to GPOs, manufacturers or CMS their immediate family members.

Similar to its treatment of indirect payments, CMS acknowledged that reporting entities that do not have “knowledge” of the ownership interests of a physician (or immediate family member of the physician) are not required to report the ownership interest. The Final Rule again uses the False Claims Act knowledge standard. Thus, GPOs and manufacturers should make reasonable inquiries to attempt to identify immediate family members of physicians.

Reporting, Public Display and Dispute Resolution

The Basics

The initial Transparency Reports and Ownership Reports will be due by March 31, 2014. Subsequent reports will be due by the 90th day of each new calendar year. Reporting entities will be permitted (and encouraged) to submit reports before that time. CMS will publish the reporting data within 90 days of data submission. Entities required to submit a Transparency Report or an Ownership Report will be required to register within the first 90 days of the calendar year and provide two points of contact to CMS.

An authorized representative for the reporting entity must provide an attestation of the accuracy of the report. The attestation should be signed by the chief executive officer, chief financial officer or chief compliance officer. CMS expects a new attestation for each annual report and an additional attestation any time data is changed or updated.

45-Day Review, Dispute Resolution and Public Display

After submission of a Transparency Report or an Ownership Report, Applicable Manufacturers, Applicable GPOs, covered recipients and physician owners and investors will have 45 days to review and provide corrections to CMS. During this period, the reporting information will not be disclosed to the public. If the information is not disputed, the reporting information will be disclosed to the public after the end of the 45-day period.

To assist physicians and teaching hospitals to identify disclosures, the Final Rule requires CMS to give notice to physicians and teaching hospitals annually using an online notification process and CMS’s listserves. Physicians and teaching hospitals will also be able to register with CMS to receive electronic notification of the review period.

If an Applicable Manufacturer, Applicable GPO, covered recipient or physician owner or investor has corrective information, they will have a 15-day dispute resolution period to negotiate and resolve the dispute. If the dispute is resolved within the dispute resolution period, Applicable Manufacturers and Applicable GPOs can update the data and provide a new attestation during the 15-day period. If the dispute is not resolved within the dispute resolution period, CMS will release the original information without change but will note that the information provided was disputed by the covered recipient or physician.

Physicians and teaching hospitals should register with CMS in advance of next year’s reporting period to take full advantage of the 45-day review period and the 15-day dispute resolution period. If a physician or teaching hospital receives electronic notification and raises the dispute early in the 45-day review period, the two sides will have until the full 60-day period expires before CMS begins the process to release the information.

If a dispute is resolved after the end of the dispute resolution period, the reporting entities will update the data and provide a new attestation. The Final Rule explains that any update received after the end of the dispute resolution period will not be automatically updated. CMS explained that it will update the database at least annually but refused to commit to making more updates.

The Proposed Rule considered whether CMS should take an active role in managing any disputes between Applicable Manufacturers, Applicable GPOs, covered recipients and physicians. In the Final Rule CMS declined invitations from numerous commentators to do so.

Registration and Pre-submission Review Not Required

CMS considered requiring manufacturers and GPOs that have no reportable payments, transfers of value, or ownership or investment interests to register with CMS. The Final Rule explains that manufacturers and GPOs should not register if they have nothing to report.

CMS also proposed requiring Applicable GPOs and Manufacturers to have a pre-submission review period. This period would have required the reporting entities to share reporting information with the applicable covered recipient or physician owner or investor. The Final Rule does not include this provision.

Penalties and Document Retention

The Final Rule includes substantial penalties for failing to timely, accurately, or completely report required information. The fines can be as high as $1,150,000 per Applicable Manufacturer or Applicable GPO, per each annual submission. CMS has indicated that errors corrected during the review and correction period will not be subject to penalties as long as the original submission was made in good faith. Correcting errors or omissions after the review and correction period, however, may result in penalties.

The Final Rule also imposes new document retention requirements. Applicable Manufacturers and Applicable GPOs are required to maintain all books, contracts, records, documents, and other evidence to support payments disclosed under the Final Rule to be maintained for a period of five years from the date the payment or other transfer of value is made available to the public by CMS.

Ober|Kaler's Comments

The Final Rule completes the initial round of implementing regulations for the Sunshine Act that started in December 2011 with the proposed rule. Its publication means that manufacturers and GPOs will need to comply with the Sunshine Act provisions of the Affordable Care Act.

CMS wisely decided to delay the effective date of information collection activities to August 1, 2013. This allows the industry some time to implement policies and procedures to meet the reporting deadline. For many entities, it will be difficult to get the necessary systems in place in time. To meet the initial reporting deadline of March 31, 2014, entities will have to work quickly.

Whether a physician has received an ownership or investment interest or a payment or transfer of value will present some initial challenges, particular with options and other quasi-ownership / quasi-compensation interests. Similarly, the rules for reporting indirect payments and for determining when the manufacturer has knowledge of an indirect covered recipient will be difficult to implement initially. Reporting entities that may have these types of issues should begin to address them well in advance of the March 31, 2014 reporting deadline.

Physicians and teaching hospitals should expect to receive inquiries from manufacturers and GPOs confirming their receipt of payments, transfers of value, and ownership and investment interests. All covered recipients should register with CMS to receive electronic notification of the data dispute review period so that both reporting entities and covered recipients have ample time to make corrections before the inaccurate or incomplete information is made public.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Donelson | Attorney Advertising

Written by:

Baker Donelson

Baker Donelson on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.